Journal article
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children
C Amlie-Lefond, DWW Shaw, A Cooper, MS Wainwright, A Kirton, RJ Felling, MG Abraham, MT MacKay, MM Dowling, M Torres, MJ Rivkin, EF Grabowski, S Lee, JE Kurz, HJ McMillan, D Barry, J Lee-Eng, RN Ichord
Stroke | Published : 2020
Abstract
Background and Purpose - Data regarding the safety and efficacy of intravenous tPA (tissue-type plasminogen activator) in childhood acute arterial ischemic stroke are inadequate. The TIPS trial (Thrombolysis in Pediatric Stroke; National Institutes of Health grant R01NS065848) - a prospective safety and dose-finding trial of intravenous tPA in acute childhood stroke - was closed for lack of accrual. TIPS sites have subsequently treated children with acute stroke in accordance with established institutional protocols supporting data collection on outcomes. Methods - Data on children treated with intravenous tPA for neuroimaging-confirmed arterial ischemic stroke were collected retrospectively..
View full abstract